About
Gerhard Hildebrandt, MD, FACP, is a hematologist and oncologist who treats cancers of the blood and lymph system. He joined MU Health Care’s Ellis Fischel Cancer Center to provide the people of mid-Missouri with excellent cancer care, including access to bone marrow transplants, CAR T cell therapy and clinical trials.
When Dr. Hildebrandt meets new patients, he likes to take his time and answer all their questions to ease their fears and help them to process and understand their diagnosis and plan ahead for treatment. The most rewarding part of his work is the bond he builds with patients and their families on the journey to the outcome they all seek, which is a cure.
In his free time, Dr. Hildebrandt enjoys swimming, working out, playing the piano and enjoying the company of his wife, his two daughters, his son and his Labrador retriever Ori.
Education & Training
Medical School
Johannes Gutenberg University Of Mainz-Fachbereich Medizin
Residency
Internal Medicine
- University Hospital Regensburg
Internal Medicine, Hematology & Oncology
- University Hospital Regensburg
Fellowship
Hematology & Oncology
- University Hospital Regensburg
Insurances
MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.
Academic Information
Research Profile
Dr. Hildebrandt’s laboratory research focuses on complications after bone marrow transplantation, including acute graft-versus-host disease and lung injury. He is exploring how the microbiome of the gut and throat affects immune responses and clinical outcomes after transplants. He is also studying the metabolic pathways that potentially could be targeted in blood cancers and after bone marrow transplants.
Research Interests
- Graft-versus-host disease.
- Impact of the metabolome and microbiome on clinical outcomes in blood cancers and after bone marrow transplantation.
Areas of Expertise
- Chimeric antigen receptor T (CAR-T) cell therapy.
- Bone marrow stem cell transplantation.
- Blood stem cell transplantation.
Publications
Dr. Hildebrandt has authored more than 130 peer-reviewed publications and book chapters. He is nationally and internationally known for his accomplishments in the field of bone marrow transplantation and blood cancer care.
- Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol. 2022 Jul 12:S1470-2045(22)00339-4. - Kumari R, Palaniyandi S, Strattan E, Hildebrandt GC.
Microbiome: an emerging new frontier in graft‑versus‑host disease.
Inflamm Res. 2021 Jan;70(1):1-5. - Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC.
Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.
PLoS One. 2013 Apr 15;8(4):e61841. - Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R.
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.
Nat Med. 2014 Jun;20(6):648-54 - Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC.
Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8. - Kumari R, Palaniyandi S, Hildebrandt GC.
Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Dig Dis Sci. 2019 Mar;64(3):669-677. - Kumari R, Palaniyandi S, Hildebrandt GC.
The microbiome-the revealing of a long time unbeknownst factor for outcome in murine models of graft-versus-host disease.
Bone Marrow Transplant. 2021 Aug;56(8):1777-1783. - Hildebrandt GC.
Pulmonary Injury and Chronic Graft-versus-Host Disease: Do We Miss the Signs and Symptoms?
Biol Blood Marrow Transplant. 2017 Oct;23(10):1605-1606. - Ramlal R, Hildebrandt GC.
Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease.
Biomedicines. 2017 May 16;5(2):23. - McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt GC, Fleischman RA, Durbin EB, Byrd JC, Wang C, Muthusamy N, Rangnekar VM, Bondada S.
Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
Blood. 2018 Jun 28;131(26):2943-2954.